» Articles » PMID: 38828412

Sex and Age Significantly Modulate Cardiovascular Disease Presentation in Type 2 Diabetes: a Large Population-based Cohort Study

Overview
Specialty Endocrinology
Date 2024 Jun 3
PMID 38828412
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: We aimed to describe and compare the incidence of the first cardiovascular event and its major subtypes, coronary heart disease (CHD), cerebrovascular disease, heart failure (HF), or peripheral artery disease (PAD), according to age and sex in a population-based cohort of individuals with type 2 diabetes (T2D) from a Mediterranean region.

Material And Methods: We used linked primary care electronic medical reports, pharmacy-invoicing data, and hospital admission disease registry records from the SIDIAP database, which contains linked data for 74% of the Catalonian population. We selected individuals with T2D aged 30 to 89 years free of cardiovascular disease (CVD). The primary outcome was the first presentation of CVD.

Results: The study cohort included 247,751 individuals (48.6% women, 66.8 ± 11.9 years). During a 6.99-year follow-up, the cumulative incidence of the first cardiovascular event was 23.4%. Men were at higher risk for CVD (hazard ratio [HR]: 1.47 95%CI: 1.45-1.50), CHD (HR: 1.52 95%CI: 1.47-1.57), cerebrovascular disease (HR:1.07 95%CI: 1.03-1.10) and PAD (HR: 2.30 95%CI: 2.21-2.39) than women but at a lower risk for HF (HR:0.70 95%CI: 0.68-0.73). CHD and PAD were the most frequent CVD presentations among men (28.1% and 27.5%) and HF (40.1%) in women. CHD predominated among young participants of both sexes, while HF predominated among women older than 65 and men older than 75.

Conclusions: In individuals with T2D, the overall risk and the type of first CVD manifestation largely varied by sex and age. This epidemiological evidence should be considered in clinical practice.

Citing Articles

First manifestation of cardiovascular disease according to age and sex in a Mediterranean country.

Ortega E, Genua I, Mata-Cases M, Roque M, Vlacho B, Real Gatius J Front Cardiovasc Med. 2024; 11:1403363.

PMID: 39355347 PMC: 11443696. DOI: 10.3389/fcvm.2024.1403363.

References
1.
Ziaeian B, Fonarow G . Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016; 13(6):368-78. PMC: 4868779. DOI: 10.1038/nrcardio.2016.25. View

2.
Gori M, Lam C, Gupta D, Santos A, Cheng S, Shah A . Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014; 16(5):535-42. DOI: 10.1002/ejhf.67. View

3.
Shah K, Xu H, Matsouaka R, Bhatt D, Heidenreich P, Hernandez A . Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017; 70(20):2476-2486. DOI: 10.1016/j.jacc.2017.08.074. View

4.
Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale C . Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2014; 3(2):105-13. PMC: 4303913. DOI: 10.1016/S2213-8587(14)70219-0. View

5.
Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View